Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10516 + Lenvatinib in advanced ccRCC
NCT07097935Phase 2Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10516 in clear cell renal cell carcinoma (ccRCC), sponsored by Hansoh Pharmaceutical Group. Started Jul 2025; status: recruiting.
02
Drugs
HS-10516
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07097935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07097935.